InvestSMART

Actinogen Medical Limited (ASX:ACW)

ALERT: Price-sensitive ASX Announcement for ACW
Current share price for ACW : $0.043 0.013 (43.33%)+
Announcement
Release
20 Oct 2025 9:04AM
Price at Release
$0.030
Full Release
download
Summary
Actinogen Medical Limited announced the early closure of pTau biomarker screening for their XanaMIA phase 2b/3 Alzheimer's disease trial due to accelerated enrolment. Originally expected to close in late November, the screening will now end on October 31, 2025. The trial, which evaluates the drug Xanamem, an oral therapy designed to control elevated brain cortisol, is aimed at participants with mild to moderate Alzheimer's Disease. The trial's robust enrolment supports the prospect of Xanamem as a promising treatment option. It is being conducted in Australia and the U.S., with projected final results expected in mid Q4 2026. This development is part of Actinogen's plan to use this trial, among others, to form the core of their marketing applications for regulatory approvals.
Key Points
  • pTau biomarker screening closes early on October 31, 2025.
  • Projected total enrolment increased to approximately 240 participants.
  • Currently 180 participants are enrolled.
  • The trial is being conducted in Australia and the U.S.
  • Primary endpoint is the Clinical Dementia Rating scale – Sum of Boxes (CDR-SB).
  • Projected topline final results expected mid Q4 2026.
  • Xanamem showed benefits on depressive symptoms in previous trials.
  • A formal interim analysis of safety and efficacy futility will occur in January 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.